Propanc Biopharma, Inc. cash flow to debt ratio of -11.76K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Propanc Biopharma, Inc.'s free cash flow has decreased 1.30K% from $-405.17K last year to $-5.68M, signaling decreasing performance

Propanc Biopharma, Inc.'s debt to equity ratio is 0.05, which means that the company's assets are healthy financed, signaling financial stability.

Propanc Biopharma, Inc.'s debt has decreased relative to shareholder equity from 0.12 last year to 0.05 today, signaling strengthened financials

Propanc Biopharma, Inc. has a net cash position, so leverage is healthy.

Propanc Biopharma, Inc.'s interest coverage ratio is -42.24, which means that the company struggles to meet interest obligations, signaling financial risk.

Propanc Biopharma, Inc. has insufficient data to evaluate this check.

Propanc Biopharma, Inc.'s short-term assets of $8.54M exceed its short-term liabilities of $3.35M

Propanc Biopharma, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Propanc Biopharma, Inc.'s return on equity of -167.51%, is lower than 15.00%, indicating bad performance

Propanc Biopharma, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Propanc Biopharma, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Propanc Biopharma, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Propanc Biopharma, Inc. has negative free cash flow, indicating cash burn

Propanc Biopharma, Inc.'s yearly earnings has increased 67.99% since last year from $-58.92M to $-18.86M, signaling increasing performance

Propanc Biopharma, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -183.49% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Propanc Biopharma, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Propanc Biopharma, Inc. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

Propanc Biopharma, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Propanc Biopharma, Inc. has insufficient data to evaluate this check.

Propanc Biopharma, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Propanc Biopharma, Inc. is overvalued relative to its fair value price of 0.00 based on Base EBITDA Valuation model

Propanc Biopharma, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Propanc Biopharma, Inc. has insufficient data to evaluate this check.

Propanc Biopharma, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Propanc Biopharma, Inc. has a price-to-book ratio of 0.22x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Propanc Biopharma, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue